The ESA Disconnect Between FDA and CMS
This article was originally published in RPM Report
Another major decision is looming at CMS on whether to open up a national coverage analysis for ESAs in the renal disease area-a MEDCAC meeting appears to be the first step. The Medicare agency previously jumped out in front of FDA on a coverage decision in the oncology setting. This time, it appears that CMS will wait to hear what FDA has to say. But FDA isn't paying much attention to CMS.
You may also be interested in...
CMS “Anemia Management” Quality Measure Relies on Monthly ESA/Hemoglobin Reports and Transfusion Level Monitoring
CMS taking a watch-and-monitor approach to controlling the use of ESAs in dialysis for 2013. That approach steps back from the trend of the past few years to specify more restrictive treatment levels to drive down further use of the products and represents a long, hard-fought success by Amgen and J&J to redefine the safety debate from when to use ESAs to efforts to avoid transfusions.
The long-awaited Risk Evaluation & Mitigation Strategy for Aranesp and Procrit is here. For the oncology indication, it requires provider training program enrollment. It may not seem like the best outcome for Amgen and J&J, but there are some upsides.
D-mab is the new EPO. At least, that's what Amgen is hoping as it awaits FDA approval for its next growth engine, denosumab (D-mab). Assuming the drug gets to market--and Amgen is very confident it will--the drug's success will depend largely on pricing.